Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

IDEXX Laboratories, Inc. Lowers FY 2012 Guidance


Friday, 20 Jul 2012 07:00am EDT 

IDEXX Laboratories, Inc. announced that for fiscal 2012, it expects revenues to be in the range of $1.30-$1.31 billion, which represents reported growth of 7% to 8% and organic growth of 8% to 9%. The decrease in expected reported revenue compared to previous guidance is due exclusively to unfavorable changes in foreign currency exchange rates, reflecting a strengthening of the U.S. dollar relative to other currencies since the date of previous guidance and EPS to be $3.05 to $3.10, compared to previous guidance of $3.07 to $3.12. The change in EPS guidance is due exclusively to the unfavorable impact of changes in foreign currency exchange rates since the date of previous guidance. Fluctuations in foreign currency exchange rates from current assumptions could have a significant positive or negative impact on actual results of operations for 2012. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $1.31 billion and EPS of $3.10 for fiscal 2012. 

Company Quote

133.38
-0.92 -0.69%
4:00pm EDT